WO2020047530A1 - Taurolidine treatment for myc-expressing tumors in mammalian bodies - Google Patents
Taurolidine treatment for myc-expressing tumors in mammalian bodies Download PDFInfo
- Publication number
- WO2020047530A1 WO2020047530A1 PCT/US2019/049266 US2019049266W WO2020047530A1 WO 2020047530 A1 WO2020047530 A1 WO 2020047530A1 US 2019049266 W US2019049266 W US 2019049266W WO 2020047530 A1 WO2020047530 A1 WO 2020047530A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- taurinamide
- taurultam
- dosage range
- taurolidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- This invention relates to therapeutic methods and compositions in general, and more particularly to therapeutic methods and compositions for the treatment of MYC-expressing tumors in mammalian bodies.
- Taurolidine is a well known antimicrobial with a published mechanism of action and antimicrobial
- Taurolidine is unstable in circulation and therefore has not been successfully developed for systemic infections. Taurolidine has demonstrated efficacy in local application for peritonitis and for prevention of infection when used as a catheter-lock solution .
- Taurolidine has recently been investigated for oncolytic activity and found to have an inhibitory effect on cell lines in culture, in combination with standard chemotherapy or alone. Despite claims that in vitro inhibitory concentrations are clinically achievable, the only published human pharmacokinetic study showed NO measurable concentration of
- taurolidine in healthy volunteers when 5 grams of taurolidine were given intravenously by 20 minute infusion. This is believed to be due to the rapid hydrolysis of taurolidine when administered
- MYC oncogenes have been widely described in solid tumors and in lymphoma/ leukemia .
- CORMEDIX-35 Taurolidine has demonstrated efficacy in treating neuroblastoma in a laboratory cell line. This cell line is known to overexpress N-myc genes.
- Taurolidine has demonstrated efficacy in treating ovarian cancer in a human ovarian cell tumor line implanted in mice. This cell line is known to overexpress C-myc genes.
- Taurolidine has demonstrated efficacy in treating lung cancer in a laboratory cell line. This cell line is known to overexpress L-myc genes.
- taurolidine and/or the hydrolysis products of taurolidine, is/are used to treat tumors that
- N-myc genes overexpress N-myc genes, C-myc genes and/or L-myc genes in mammalian bodies.
- tumors that may overexpress N-myc genes, C-myc genes and/or L-myc
- CORMEDIX-35 genes include, but are not limited to, lymphoma, melanoma, multiple myeloma, neuroblastoma, colon, breast and lung cancers.
- the preferred hydrolysis products of taurolidine may comprise at least one from the group consisting of :
- taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam: 7 taurinamide : 1 methylene glycol.
- the taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- the taurultam is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between
- the taurinamide is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- the methylene glycol is given with a dosage range of from 2.5 mg/kg to 160 mg/kg, with optimal range between 2.5 mg/kg and 30 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- the taurultam and taurinamide (in a ratio of 1 taurultam:7 taurinamide) is given with a dosage range of taurultam from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 40 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range from 35 mg/kg to 40 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- taurultam, taurinamide and methylene glycol (in a ratio of 1 taurultam: 7 taurinamide : 1 methylene glycol) is given with a dosage range of taurultam from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 40 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range from 35 mg/kg to 40 mg/kg, further combined with methylene glycol with a dosage range of from 2.5 mg/kg to 160 mg/kg with optimal range from 5 mg/kg to 40 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- the taurolidine, and/or the hydrolysis products of taurolidine can be given systemically, preferably intramuscularly or intravenously.
- the taurolidine, and/or the hydrolysis products of taurolidine is/are delivered systemically in a
- taurolidine or the hydrolysis products of taurolidine, can reach the site of the tumor without premature degradation, whereupon
- taurolidine can treat the tumor.
- the taurolidine and/or the hydrolysis products of taurolidine can be delivered in the form of a nanoparticle, where the nanoparticle comprises a core of the taurolidine and/or the hydrolysis products of taurolidine and an exterior coating which is configured to prevent premature exposure of the taurolidine and/or the hydrolysis products of
- the exterior coating breaks down as the nanoparticle travels from the site of the insertion to the site of the tumor so as to release the taurolidine and/or the hydrolysis products of taurolidine intact at the site of the tumor.
- the coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
- the taurolidine and/or the hydrolysis products of taurolidine may be delivered using a polymer system which is configured to delay premature degradation of the active ingredient.
- the taurolidine and/or the hydrolysis products of taurolidine may be "pegylated” using polyethylene glycols (PEGs) to delay premature degradation of the active ingredient.
- taurolidine, and/or the hydrolysis products of taurolidine may be delivered as either a single agent or in combination with other oncolytic agents and/or radiotherapy.
- Fig. 1 is a graph showing that leukemia cell lines appear more sensitive to the effects of
- taurolidine compared to healthy lymphocytes in vitro ( not in vivo ) ;
- Fig. 2 is a graph showing that neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
- Figs. 3-6 are graphs or photographs showing that taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice has efficacy in IMR5 tumors and measurable efficacy in SK-N-AS tumors in vivo (not in vitro) ;
- Figs. 7 and 8 are graphs showing that
- Fig. 9 is a chart showing the effect of delayed administration of a single 3-day i.p.
- taurolidine (20 mg/mouse/in ection) on the occurrence of i.p. human tumor xenografts in female nude mice after the i.p. administration of 5 x 10 6 SKOV-3 human ovarian tumor cells;
- Fig. 10 illustrates the mechanism for the hydrolysis of taurolidine
- Fig. 11 is a chart showing the mean
- Fig. 12 is a chart showing the mean
- Taurolidine was developed as an anti-infective, but has been found to have oncolytic activity against neuroblastoma tumors in a laboratory cell line. This laboratory cell line is known to overexpress N-myc
- taurolidine has been found to have surprising oncolytic activity in cell cultures of human cancer cells expressing N-myc, and now in a rodent cancer model based on an N-myc expressing human cancer cell line.
- neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
- taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice showed dramatic efficacy in IMR5 tumors and measurable efficacy in SK-N-AS tumors in vivo (not in vitro) .
- CORMEDIX-35 treat mice with a different cell line (SK-N-AS) also derived from neuroblastoma, though overall survival of the mice implanted with the tumor was not
- Taurolidine has also demonstrated efficacy in treating ovarian cancer in a human ovarian cell tumor line implanted in mice.
- This cell line is known to overexpress C-myc genes.
- Fig. 9 shows the effect of delayed administration of a single 3-day i.p. ( intraperitoneal ) bolus injection regimen of taurolidine (20 mg/mouse/in ection) on the occurrence of i.p. human tumor xenografts in female nude mice after the i.p. administration of 5 x 10 6 SKOV-3 human ovarian tumor cells.
- taurolidine therapy was initiated on the day of tumor cell
- mice in all of the groups were sacrificed, and the peritoneal cavity was examined for the presence of tumors.
- CORMEDIX-35 number of animals in each group ranged from 15-21 (Cancer Res., 2001 Sep 15; 61 ( 18 ) : 6816-21 ,
- Taurolidine cytotoxic and mechanistic evaluation of a novel antineoplastic agent, Calabresi Pi, Goulette FA, Darnowski JW) .
- Taurolidine has also demonstrated efficacy in treating lung cancer in a laboratory cell line.
- This cell line is known to overexpress L-myc genes.
- taurolidine is/are used to treat tumors that
- N-myc genes overexpress N-myc genes, C-myc genes and/or L-myc genes in mammalian bodies.
- tumors that may overexpress N-myc genes, C-myc genes and/or L-myc genes include, but are not limited to, lymphoma, melanoma, multiple myeloma, neuroblastoma, colon, breast and lung cancers.
- Fig. 10 The mechanism for the hydrolysis of taurolidine is shown in Fig. 10.
- the preferred hydrolysis products of taurolidine that may be used to treat tumors that overexpress N-myc genes, C-myc genes
- CORMEDIX-35 and/or L-myc genes in mammalian bodies may comprise at least one from the group consisting of:
- taurultam 7 taurinamide
- taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam: 7 taurinamide : 1 methylene glycol.
- the taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- the taurultam is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- the mean pharmacokinetic parameters of taurultam are shown in Fig. 11.
- the taurinamide is given with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 60 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- the mean pharmacokinetic parameters of taurinamide are shown in Fig. 12.
- the methylene glycol is given with a dosage range of from 2.5 mg/kg to 160 mg/kg, with optimal range between 2.5 mg/kg and 30 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- the taurultam and taurinamide (in a ratio of 1 taurultam:7 taurinamide) is given with a dosage range of taurultam from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 40 mg/kg, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range from 35 mg/kg to 40 mg/kg, from once daily through weekly, for an effective period of time based on individual patient response.
- CORMEDIX-35 glycol is given with a dosage range of taurultam from 5 mg/kg to 280 mg/kg, with optimal range between 5 mg/kg and 40 mg/kg, from once daily through weekly, combined with taurinamide with a dosage range of from 5 mg/kg to 280 mg/kg, with optimal range from 35 mg/kg to 40 mg/kg, further combined with methylene glycol with a dosage range of from 2.5 mg/kg to 160 mg/kg with optimal range from 5 mg/kg to 40 mg/kg from once daily through weekly, for an effective period of time based on individual patient response.
- AUC 0-inf Taurultam/AUC 0-inf Taurinamide 42.9/312.7
- the target ratio when giving taurultam and taurinamide in combination is 0.14 or 1:7. And the target ratio when giving
- CORMEDIX-35 taurultam and taurinamide and methylene glycol in combination is 1:7:1.
- the taurolidine, and/or the hydrolysis products of taurolidine can be given systemically, preferably intramuscularly or intravenously.
- taurolidine is/are delivered systemically in a
- taurolidine can treat the tumor.
- the taurolidine, and/or the hydrolysis products of taurolidine is/are delivered in the form of a nanoparticle, where the nanoparticle comprises a core comprising taurolidine and/or the hydrolysis products of taurolidine, and an exterior coating which is configured to prevent premature exposure of the taurolidine, and/or the hydrolysis products of
- the exterior coating breaks down as the nanoparticle travels from the site of insertion to the site of the tumor so as to release the
- the coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
- the coating can be created from
- the coating may also be associated with glycols such as polyethylene glycols (PEGs), which can either be linear or multi-arm structures.
- PEGs polyethylene glycols
- the nanoparticle may comprise an excipient (e.g., a buffer for providing enhanced hydrolytic stability of the taurolidine and/or
- the nanoparticle can further comprise a coating, wherein the coating is configured to target the nanoparticle to the site of a tumor so as to improve the efficacy of the taurolidine and/or hydrolysis product for treatment of the tumor.
- the coating comprises binding molecules which are configured to target delivery of the nanoparticle to specific tissue .
- taurolidine may be delivered using a polymer system which is configured to delay premature degradation of the taurolidine, and/or the hydrolysis products of taurolidine, and/or to optimize the release properties of the taurolidine, and/or the hydrolysis products of taurolidine.
- the taurolidine, and/or the hydrolysis products of taurolidine may be "pegylated” using polyethylene glycols (PEGs) to delay premature degradation of the taurolidine, and/or the hydrolysis products of
- taurolidine and/or to optimize the release properties of the taurolidine, and/or the hydrolysis products of taurolidine .
- the taurolidine (and/or the hydrolysis products of taurolidine) may be delivered as either a single agent or in combination with other oncolytic agents and/or radiotherapy.
- oncolytic agents that can be combined with taurolidine and/or the hydrolysis products of taurolidine for systemic
- CORMEDIX-35 delivery are platinum compounds (cisplatin,
- alkylating agents cyclophosphamide, ifosfamide, melphalan, topoisomerase II inhibitor
- vinca alkaloids vincristine
- topoisomerase I inhibitors topotecan and irinotecan
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019331913A AU2019331913A1 (en) | 2018-08-31 | 2019-09-03 | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
EP19854097.3A EP3843747A4 (en) | 2018-08-31 | 2019-09-03 | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
KR1020217009412A KR20210054544A (en) | 2018-08-31 | 2019-09-03 | Taurolidine Treatment for MYC-expressing Tumors in Mammalian Body |
JP2021511591A JP2021535167A (en) | 2018-08-31 | 2019-09-03 | Taurolidine treatment of MYC-expressing tumors in the mammalian body |
CA3111100A CA3111100A1 (en) | 2018-08-31 | 2019-09-03 | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
CN201980072806.2A CN113226325A (en) | 2018-08-31 | 2019-09-03 | Treatment of MYC expressing tumors in mammals with taurolidine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862725650P | 2018-08-31 | 2018-08-31 | |
US62/725,650 | 2018-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020047530A1 true WO2020047530A1 (en) | 2020-03-05 |
Family
ID=69643283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/049266 WO2020047530A1 (en) | 2018-08-31 | 2019-09-03 | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3843747A4 (en) |
JP (1) | JP2021535167A (en) |
KR (1) | KR20210054544A (en) |
CN (1) | CN113226325A (en) |
AU (1) | AU2019331913A1 (en) |
CA (1) | CA3111100A1 (en) |
WO (1) | WO2020047530A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593665A (en) * | 1990-03-15 | 1997-01-14 | Ed Geistlich S ohne AG f ur Chemische Industrie | Pharmaceutical compositions |
US20020091123A1 (en) * | 1998-07-31 | 2002-07-11 | Redmond H. Paul | Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases |
US20050119254A1 (en) * | 2003-09-29 | 2005-06-02 | Ed. Geistlich Soehne Ag | Treatment of mesothelioma |
WO2007020509A1 (en) * | 2005-08-15 | 2007-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth |
US20130089606A1 (en) * | 2010-06-01 | 2013-04-11 | Geistlich Pharma Ag | Methods and compositions for oral pharmaceutical therapy |
US20170196875A1 (en) * | 2016-01-11 | 2017-07-13 | Cormedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60030770T2 (en) * | 1999-12-06 | 2007-09-06 | Rhode Island Hospital | USE OF TAUROLIDINE OR TAURULTAM FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF OVARIAN CARCINOMES |
CN100519525C (en) * | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | Aromatic sulfones and their medical use |
US20080171738A1 (en) * | 2001-04-03 | 2008-07-17 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of Breast Cancer |
WO2007077528A1 (en) * | 2006-01-06 | 2007-07-12 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam |
JP6933659B2 (en) * | 2016-03-18 | 2021-09-08 | ガイストリッヒ・ファルマ・アーゲーGeistlich Pharma Ag | How to treat triple-negative breast cancer |
-
2019
- 2019-09-03 EP EP19854097.3A patent/EP3843747A4/en active Pending
- 2019-09-03 AU AU2019331913A patent/AU2019331913A1/en active Pending
- 2019-09-03 CN CN201980072806.2A patent/CN113226325A/en active Pending
- 2019-09-03 JP JP2021511591A patent/JP2021535167A/en active Pending
- 2019-09-03 WO PCT/US2019/049266 patent/WO2020047530A1/en unknown
- 2019-09-03 KR KR1020217009412A patent/KR20210054544A/en unknown
- 2019-09-03 CA CA3111100A patent/CA3111100A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593665A (en) * | 1990-03-15 | 1997-01-14 | Ed Geistlich S ohne AG f ur Chemische Industrie | Pharmaceutical compositions |
US20020091123A1 (en) * | 1998-07-31 | 2002-07-11 | Redmond H. Paul | Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases |
US20050119254A1 (en) * | 2003-09-29 | 2005-06-02 | Ed. Geistlich Soehne Ag | Treatment of mesothelioma |
WO2007020509A1 (en) * | 2005-08-15 | 2007-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth |
US20130089606A1 (en) * | 2010-06-01 | 2013-04-11 | Geistlich Pharma Ag | Methods and compositions for oral pharmaceutical therapy |
US20170196875A1 (en) * | 2016-01-11 | 2017-07-13 | Cormedix Inc. | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |
Also Published As
Publication number | Publication date |
---|---|
CN113226325A (en) | 2021-08-06 |
EP3843747A1 (en) | 2021-07-07 |
EP3843747A4 (en) | 2022-12-28 |
CA3111100A1 (en) | 2020-03-05 |
JP2021535167A (en) | 2021-12-16 |
KR20210054544A (en) | 2021-05-13 |
AU2019331913A1 (en) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170266293A1 (en) | Methods of treating cancers with therapeutic nanoparticles | |
CZ290120B6 (en) | Compound composition of paclitaxel, docetaxel or analog thereof | |
AU2008260203B2 (en) | Metal complexes incorporated within biodegradable nanoparticles and their use | |
Naraharisetti et al. | In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma | |
Li et al. | Innovative irinotecan-loaded nanomicelles will enter phase I clinical trial in 2021 | |
US20230390300A1 (en) | Neuroblastoma treatment with taurolidine hydrolysis products | |
JP2009292837A (en) | Method for treating cancer having greater efficacy and reduced adverse effect | |
US20220323451A1 (en) | Taurolidine treatment for myc-expressing tumors in mammalian bodies | |
Sapra et al. | Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin’s lymphoma | |
WO2020047530A1 (en) | Taurolidine treatment for myc-expressing tumors in mammalian bodies | |
KR20210050544A (en) | Neuroblastoma treatment using taurolidine hydrolysis products | |
Zhang et al. | Co-delivery of sorafenib and metformin from amphiphilic polypeptide-based micelles for colon cancer treatment | |
US20190381058A1 (en) | Methods and compositions for treating neuroblastoma in a juvenile mammalian body | |
CN113164491A (en) | Methods and compositions for treating neuroblastoma in young mammals | |
Karmali et al. | Combinatorial treatment with carboxyamidotriazole-orotate and temozolomide in sc-implanted human LOX IMVI melanoma xenografts | |
WO2008135792A1 (en) | Pm00104 compound for use in cancer therapy | |
AKTAŞ et al. | Neuroblastoma-targeted Anticancer Drug Delivery | |
Akotiah et al. | Drug Targeting and Therapeutic Management of Chronic Myeloid Leukemia: Conventional and Nanotherapeutic Drug Options | |
AU2016253153A1 (en) | Compositions for the treatment of cancer | |
Sadat | Nanodelivery of novel inhibitors of DNA repair for enhanced cancer therapy | |
JP2023108999A (en) | Anticancer drug-containing sheet | |
WO2023196545A1 (en) | Cancer treatments using mta-cooperative prmt5 inhibitors | |
CN117083086A (en) | Use of apyrase in radiation and/or anticancer therapy adjuvant therapy | |
Cui et al. | Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model | |
WO2001000240A2 (en) | Antitumor compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19854097 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3111100 Country of ref document: CA Ref document number: 2021511591 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217009412 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019854097 Country of ref document: EP Effective date: 20210331 |
|
ENP | Entry into the national phase |
Ref document number: 2019331913 Country of ref document: AU Date of ref document: 20190903 Kind code of ref document: A |